Navigation Links
Boston Scientific Transvaginal Mesh Lawsuits in Massachusetts State Court Move Forward After a Defense Verdict in First Trial, Schlichter, Bogard & Denton Reports
Date:8/13/2014

St. Louis, M (PRWEB) August 13, 2014

Kristine Kraft, a partner at Schlichter, Bogard & Denton, LLP, reports that the Massachusetts state court trials involving transvaginal mesh (TVM) devices will move forward after a defense verdict in favor of Boston Scientific was rendered on July 29, 2014. (Albright v. Boston Scientific Corp., Case No. 12-909, Middlesex County Superior Court, Massachusetts).

Following nearly a three-week trial, Plaintiff Diane Albright’s design defect and failure to warn case involving Boston Scientific, the manufacturer of her transvaginal mesh device, went to a jury on July 28, 2014. Before a jury verdict could be rendered, it was required that eleven of the thirteen jurors agree when answering the jury questions -- and that threshold was met. The majority of jurors decided that Albright received adequate informed consent regarding the risks associated with the transvaginal mesh device manufactured by Boston Scientific.

Boston Scientific is facing thousands of other claims over their transvaginal mesh devices. According to the Judicial Panel on Multidistrict Litigation's most recent report, nearly 12,200 of those claims against Boston Scientific have been consolidated in a Multidistrict Litigation (In re: Boston Scientific Corp. Pelvic Repair System Products Liability Litigation, MDL 2326, S.D. WV) before The Honorable Judge Joseph R. Goodwin in the United States District Court for the Southern District of West Virginia. The first federal trial in MDL 2326 is scheduled for November 3, 2014. In Massachusetts state court, there are nearly 1,700 claims still pending before The Honorable Judge Diane Kottmyer, the judge that oversaw the Albright case. The next Massachusetts state court trial is set for August 11, 2014.

Thousands of women allege that they have experienced complications from these transvaginal mesh devices, including device erosion, organ perforation, intense pain, inability to have sexual intercourse, infection, and the need to undergo multiple revision surgeries. “We continue to hear from individuals who allege to have suffered serious injuries associated with these transvaginal mesh devices,” says Kraft. “Despite the defense verdict in the first state court case against Boston Scientific, we will continue to fight for the rights of women alleging serious injuries due to these products.” The attorneys at Schlichter, Bogard & Denton are currently representing a multitude of women who allege to have suffered injuries as a result of TVM devices.

About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in national litigations involving dangerous pharmaceutical medications, unsafe medical devices and toxic torts, including but not limited to: In re: Testosterone Replacement Therapy Products Liability Litigation (MDL 2545, Case No. 14-md-2545, N.D. Ill.), In re: Pradaxa® (Dabigatran Etexilate) Products Liability (MDL 2385, Case No. 12-md-2385, S.D. Ill.), In re: E.I. Du Pont de Nemours and Company C-8 Personal Injury Litigation (MDL 2433, Case No. 13-md-2433, S.D. Ohio), In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100, Case No. 09-md-2100, S.D. Ill.), In re: NuvaRing® Products Liability Litigation (MDL 1964, Case No. 08-md-1964, E.D. Mo.), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909, Case No. 08-md-50000, N.D. Ohio), and In re: Ortho Evra® Products Liability Litigation (MDL 1742, Case No. 06-md-40000, N.D. Ohio).

The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death.

If you or a loved one have suffered serious injuries associated with transvaginal mesh products, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. We are available to either handle these cases or work as co-counsel, so other attorneys with these types of cases are invited to contact an attorney at the firm to explore this opportunity.

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12091311.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Boston Marathon bombing caregivers still grappling with tragedy one year later
2. My Sky Exhibit Opens at Boston Children’s Museum
3. Brain responses to emotional images predict PTSD symptoms after Boston Marathon bombing
4. Boston Children’s Museum Presents A Distant Episode Gallery Exhibit
5. Boston Z Realty Expands Variety of Languages Spoken by Agents
6. RSNA: Researchers Assess Emergency Radiology Response After Boston Marathon Bombings
7. Researchers assess emergency radiology response after Boston Marathon bombings
8. Boston University researchers receive NIH funding for genetic research in Alzheimers disease
9. Boston University researchers and collaborators receive $12.6 million NIH grant for AD
10. Boston Medical Center cardiologist Gary Balady, M.D., receives AHAs Paul Dudley White Award
11. American Society for Microbiology to host 114th General Meeting in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... 2017 , ... During the last week of March, Chad Kawa, MD of ... in the local community. , Colon cancer is the second leading cause of ... while it is small, confined and easier to treat. If you are 50 or ...
(Date:3/29/2017)... Diego, CA (PRWEB) , ... March 29, 2017 , ... ... and up to 300,000 people each year develop other types of metastatic brain tumors(3). ... quickly throughout the brain(3). As efforts focus on finding more effective treatment options, the ...
(Date:3/29/2017)... ... 29, 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has ... that assists dog owners in creating legally-enforceable pet trusts for their canine companions. ... step to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... EAST HANOVER, N.J. , March 29, 2017 ... and Drug Administration (FDA) has accepted the company,s ... review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen ... refractory (r/r) pediatric and young adult patients with ... first BLA submission by Novartis for a CAR-T. ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" report ... The ... from its current market size in 2016. The Untapped Proton Therapy Market ... 1 Billion USD in 2016. Proton Therapy plays an ...
(Date:3/29/2017)... , March 29, 2017  Zynex (OTCQB: ZYXI), an ... sale of non-invasive medical devices for pain management, stroke ... it will host the Company,s 2016 full-year investor webcast ... Time.) The Company expects to file its ... ...
Breaking Medicine Technology: